Methyl aminolevulinate (Metvix®) HTA ID: 19049
Methyl aminolevulinate for the treatment of: thin or non-hyperkeratotic and non-pigmented actinic keratoses on the face and scalp, when other therapies are considered less appropriate; superficial and/or nodular basal cell carcinoma unsuitable for other available therapies; and squamous cell carcinoma in situ (Bowen´s disease) when surgical excision is considered less appropriate.
NCPE Assessment Process | Complete |
Rapid review commissioned | 06/11/2019 |
Rapid review completed | 18/12/2019 |
Rapid Review outcome | A full HTA is not recommended. The NCPE recommends that methyl aminolevulinate (Metvix®) not be considered for reimbursement at the submitted price*. |
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.